… No definite therapeutic agents or vaccines for COVID-19 are existing. Several therapies,
such as remdesivir, ribavirin, and favipiravir, are under investigation and clinical trial. The use of …

… In a more elaborate randomized open-label controlled multicenter trial, 240 patients were
randomized (1:1) to receive conventional COVID-19 therapy along with either umifenovir or …

… Presently, we need more therapeutic molecules for this COVID-19 outbreak. The severity …
IL-6 is a type of pro-inflammatory cytokine which release in the severe COVID-19 patients. This …

… response to coronavirus infection and the related therapeutic options will be presented. …
to be further evaluated as a therapeutic option for COVID-19 patients, although there are some …

… Since the beginning of the pandemic, many studies have been conducted using remdesivir
and it has been identified as a potential COVID-19 therapeutic candidate due to its ability to …

… [ 25 ] As cytokine storm is a pathognomonic feature of COVID-19, inhibition of these pro-inflammatory
cytokines may theoretically prove useful (eg, inhibition of IL-6 by tocilizumab).[ 24 ] …

… It could be an attractive therapeutic option to control the cytokine storm in patients with
COVID19. Itolizumab is under phase II clinical study in India for the management of moderate to …

… there was no definite therapy and vaccine for COVID-19. So, as COVID-19 has called ideas
for … ) as a treatment of COVID-19, which received less attention compared with other potential …

The COVID-19 patients were first detected in China, in December 2019, then the novel virus
with associated pneumonia and other diseases spread quickly to worldwide becoming a …

… ) is SARS-CoV2, the cause of COVID-19. At the time of submission of this review SARS…
COVID-19, pathophysiological mechanisms, and already available and future therapeutic options …